Meeting
2015 ASCO Annual Meeting
Evaluation of possible linkage between everolimus benefit in estrogen receptor (ER)-positive breast cancer and genomic alterations of the PI3K/AKT/mTOR pathway.
Authors
Esther P. Black
University of Kentucky, Lexington, KY
Esther P. Black , Edward H. Romond , Juliann Chmielecki , James Sun , Vera Kadamyan , Mara D. Chambers , Rachel Lauren Stewart , Emily Van Meter Dressler , Murtaza Mehdi , Craig Horbinski , Suleiman Alfred Massarweh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 530)
DOI
10.1200/jco.2015.33.15_suppl.530
Abstract #
530
Poster Bd #
18
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Genomic landscape and immune phenotype of malignant pleural mesothelioma.
First Author: Meera Patel
Poster
2017 Genitourinary Cancers Symposium
Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA.
First Author: Werner J. Struss
Poster
2015 ASCO Annual Meeting
Effect of mutations in distinct components of the PI3K/AKT/mTOR pathway on sensitivity to endocrine therapy in estrogen receptor (ER)-positive breast cancer.
First Author: Suleiman Alfred Massarweh
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West